Elanco in licensing pact with Australia’s Neurizon

Henrik Sorensen

Australia-based biotech Neurizon Therapeutics (OTCPK:PAAFF) has inked an exclusive global licensing agreement with Elanco Animal Health (NYSE:ELAN) to obtain rights for monepantel, the active pharmaceutical ingredient in its lead asset NUZ-001.

Neurizon expects the deal to accelerate the development of